BN Business News
Add your company to Business Communicator →

Business · 10/05/2024Updated: 10/16/2026 · 1 min read

Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors

Summary

The National Cancer Institute is contemplating the grant of an Exclusive Patent License to McSAF Inside Oncology SAS for practicing inventions related to CD56-Positive Tumors.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights

Business insights →